BMS Gets FDA Priority Review for Expanded Use of Cancer Drug Opdivo

Nov 17, 2015


Bristol-Myers Squibb Company announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.

BMS is looking to get Opdivo approved for the treatment of patients with advanced renal cell carcinoma -- kidney cancer -- who have received prior anti-angiogenic therapy.The projected FDA action date is March 16, 2016.

Last month, FDA expanded approved use of Opdivo to advanced lung cancer. Currently, Opdivo is approved for both lung cancer and metastatic melanoma indications. 

Read the Zacks press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments